PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
63.16%
Cash & equivalents changing by 63.16% while Medical - Pharmaceuticals maintains stable levels. Benjamin Graham would examine if this divergence is justified.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-37.14%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
3.40%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-22.78%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
19.58%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
4.22%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-6.52%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-6.52%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-10.15%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
101.54%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-90.69%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.79%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
8.47%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
13.66%
Payables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
45.41%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
270.33%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
-158.90%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
12.76%
Above 1.5x Medical - Pharmaceuticals median of 4.50%. Jim Chanos suspects potential working capital strain.
-8.72%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-54.08%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-4.64%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
9.96%
Above 1.5x Medical - Pharmaceuticals median of 1.62%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
7.14%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-80.00%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
6.41%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
8.47%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
-99.98%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
25.46%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-1749.31%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.